Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Wins Injunction To Block Apotex Biosimilar

This article was originally published in Scrip

Executive Summary

A Florida district court has imposed a preliminary injunction that would block Apotex Corp. from marketing its pegfilgrastim biosimilar of Amgen Inc.'s long-acting human granulocyte colony-stimulating factor Neulasta for at least six months after the medicine gains the FDA's approval.

Advertisement
Advertisement
UsernamePublicRestriction

Register